ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina

a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JAMISON BRYCE TUTTLE, SIMONE SCIABOLA, JACLYN LOUISE HENDERSON, TRAVIS T. WAGER, JOSEPH MICHAEL YOUNG, BETHANY LYN KORMOS, PATRICK ROBERT VERHOEST, NANDINI CHATURBHAI PATEL, JOSEPH WALTER TUCKER, THOMAS ALLEN CHAPPIE
Format: Patent
Sprache:por
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator JAMISON BRYCE TUTTLE
SIMONE SCIABOLA
JACLYN LOUISE HENDERSON
TRAVIS T. WAGER
JOSEPH MICHAEL YOUNG
BETHANY LYN KORMOS
PATRICK ROBERT VERHOEST
NANDINI CHATURBHAI PATEL
JOSEPH WALTER TUCKER
THOMAS ALLEN CHAPPIE
description a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão. The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_BR112018013955A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BR112018013955A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_BR112018013955A23</originalsourceid><addsrcrecordid>eNrjZHDLyUxPzCtJLVZISVVIyS9IzM3MS1RIMQZxzXTMdSx0LHVLUkuKEnUzMlOK8nVNM3QLMosyU_KjjXSMdVNiE6tSC4A6eBhY0xJzilN5oTQ3g6qba4izh25qQX58anFBYnJqXmpJvFOQoaGRgaGFgaGxpampo5ExseoAWNcyYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><source>esp@cenet</source><creator>JAMISON BRYCE TUTTLE ; SIMONE SCIABOLA ; JACLYN LOUISE HENDERSON ; TRAVIS T. WAGER ; JOSEPH MICHAEL YOUNG ; BETHANY LYN KORMOS ; PATRICK ROBERT VERHOEST ; NANDINI CHATURBHAI PATEL ; JOSEPH WALTER TUCKER ; THOMAS ALLEN CHAPPIE</creator><creatorcontrib>JAMISON BRYCE TUTTLE ; SIMONE SCIABOLA ; JACLYN LOUISE HENDERSON ; TRAVIS T. WAGER ; JOSEPH MICHAEL YOUNG ; BETHANY LYN KORMOS ; PATRICK ROBERT VERHOEST ; NANDINI CHATURBHAI PATEL ; JOSEPH WALTER TUCKER ; THOMAS ALLEN CHAPPIE</creatorcontrib><description>a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão. The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.</description><language>por</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20181211&amp;DB=EPODOC&amp;CC=BR&amp;NR=112018013955A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76418</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20181211&amp;DB=EPODOC&amp;CC=BR&amp;NR=112018013955A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JAMISON BRYCE TUTTLE</creatorcontrib><creatorcontrib>SIMONE SCIABOLA</creatorcontrib><creatorcontrib>JACLYN LOUISE HENDERSON</creatorcontrib><creatorcontrib>TRAVIS T. WAGER</creatorcontrib><creatorcontrib>JOSEPH MICHAEL YOUNG</creatorcontrib><creatorcontrib>BETHANY LYN KORMOS</creatorcontrib><creatorcontrib>PATRICK ROBERT VERHOEST</creatorcontrib><creatorcontrib>NANDINI CHATURBHAI PATEL</creatorcontrib><creatorcontrib>JOSEPH WALTER TUCKER</creatorcontrib><creatorcontrib>THOMAS ALLEN CHAPPIE</creatorcontrib><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><description>a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão. The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHDLyUxPzCtJLVZISVVIyS9IzM3MS1RIMQZxzXTMdSx0LHVLUkuKEnUzMlOK8nVNM3QLMosyU_KjjXSMdVNiE6tSC4A6eBhY0xJzilN5oTQ3g6qba4izh25qQX58anFBYnJqXmpJvFOQoaGRgaGFgaGxpampo5ExseoAWNcyYg</recordid><startdate>20181211</startdate><enddate>20181211</enddate><creator>JAMISON BRYCE TUTTLE</creator><creator>SIMONE SCIABOLA</creator><creator>JACLYN LOUISE HENDERSON</creator><creator>TRAVIS T. WAGER</creator><creator>JOSEPH MICHAEL YOUNG</creator><creator>BETHANY LYN KORMOS</creator><creator>PATRICK ROBERT VERHOEST</creator><creator>NANDINI CHATURBHAI PATEL</creator><creator>JOSEPH WALTER TUCKER</creator><creator>THOMAS ALLEN CHAPPIE</creator><scope>EVB</scope></search><sort><creationdate>20181211</creationdate><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><author>JAMISON BRYCE TUTTLE ; SIMONE SCIABOLA ; JACLYN LOUISE HENDERSON ; TRAVIS T. WAGER ; JOSEPH MICHAEL YOUNG ; BETHANY LYN KORMOS ; PATRICK ROBERT VERHOEST ; NANDINI CHATURBHAI PATEL ; JOSEPH WALTER TUCKER ; THOMAS ALLEN CHAPPIE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_BR112018013955A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>por</language><creationdate>2018</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>JAMISON BRYCE TUTTLE</creatorcontrib><creatorcontrib>SIMONE SCIABOLA</creatorcontrib><creatorcontrib>JACLYN LOUISE HENDERSON</creatorcontrib><creatorcontrib>TRAVIS T. WAGER</creatorcontrib><creatorcontrib>JOSEPH MICHAEL YOUNG</creatorcontrib><creatorcontrib>BETHANY LYN KORMOS</creatorcontrib><creatorcontrib>PATRICK ROBERT VERHOEST</creatorcontrib><creatorcontrib>NANDINI CHATURBHAI PATEL</creatorcontrib><creatorcontrib>JOSEPH WALTER TUCKER</creatorcontrib><creatorcontrib>THOMAS ALLEN CHAPPIE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JAMISON BRYCE TUTTLE</au><au>SIMONE SCIABOLA</au><au>JACLYN LOUISE HENDERSON</au><au>TRAVIS T. WAGER</au><au>JOSEPH MICHAEL YOUNG</au><au>BETHANY LYN KORMOS</au><au>PATRICK ROBERT VERHOEST</au><au>NANDINI CHATURBHAI PATEL</au><au>JOSEPH WALTER TUCKER</au><au>THOMAS ALLEN CHAPPIE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><date>2018-12-11</date><risdate>2018</risdate><abstract>a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão. The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language por
recordid cdi_epo_espacenet_BR112018013955A2
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A38%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JAMISON%20BRYCE%20TUTTLE&rft.date=2018-12-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EBR112018013955A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true